After ten days of intense negotiations, the European Pharmaceutical Agency (EMA) conditionally accepted Ruixing's data security framework plan. The key concession was allowing real-time synchronization of all EU patient treatment data between the main data center in China and the mirror center in Frankfurt.
The simultaneously established "Sino-European Medical Data Security Supervision Committee" will have dual veto rights—either party can suspend cross-border data flow if they believe data access may endanger patient privacy or national security.
"This is a plan that no party is satisfied with but all can accept," evaluated Huang Jiacai at an internal meeting, "The EMA has preserved its regulatory authority, we've secured the market, and the European giants have secured their ticket to continue negotiations."
"What about the costs?" a director asked.
